Korro Bio, Inc. Common Stock (KRRO) Stock Price
KRROStock
$8.49−82.53%52W
Market Cap$125.02M
P/E—
PEG Ratio—
Div yield—
Beta3.29
KRRO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-48.96%
Price vs S&P 500 (4W)-13.60%
VGM Score27.50
KRRO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.28 | -$1.07 | +16.33%(+$0.21) | |
| Q1 2026 | -$1.98 | -$1.69 | +14.73%(+$0.29) | |
| Q4 2025 | -$2.14 | -$1.65 | +22.94%(+$0.49) | |
| Q3 2025 | -$2.68 | -$1.92 | +28.29%(+$0.76) | |
| Q2 2025 | -$2.59 | -$2.74 | -5.61%(-$0.15) |
KRRO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.06
4.13
4.13
4.17
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
KRROKorro Bio, Inc. Common Stock | C | F | D | 19.6x | -62.1% | — | — | $8.49 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Korro Bio, Inc. Common Stock
Korro Bio is a biopharmaceutical company developing RNA-editing genetic medicines to treat rare and prevalent diseases. The company's proprietary platform leverages the body's natural RNA editing process to create precise, transient single-base edits with greater reversibility than traditional DNA-editing approaches. This differentiated technology positions Korro Bio to address significant unmet medical needs in genetic medicine with enhanced precision and tunability.